Author

W.K. Alfred Yung

UT MD Anderson Cancer Center - Cited by 50,844 - Neuro-oncology - tumor biology

Biography

W.K. Alfred Yung worked at UT MD Anderson Cancer Center, Neuro-Oncology, Margaret and Ben Love Chair of Clinical Care. Skills and Expertise: Glioma, Brain Tumors, Astrocytoma, Glioblastoma Multiforme (GBM), Neuro-Oncology, Pre-clinical Development,cell biology,stem cells,Brain cells,Cell Science .
Title
Cited by
Year
Longitudinal molecular trajectories of diffuse glioma in adults
FP Barthel, KC Johnson, FS Varn, AD Moskalik, G Tanner, E Kocakavuk, ...Nature 576 (7785), 112-120, 2019201
310
2019
Molecular mechanisms of treatment resistance in glioblastoma
A Ou, WKA Yung, N MajdInternational journal of molecular sciences 22 (1), 351, 2020202
96
2020
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
J De Groot, M Penas-Prado, K Alfaro-Munoz, K Hunter, BL Pei, B O’Brien, ...Neuro-oncology 22 (4), 539-549, 2020202
88
2020
Glioma progression is shaped by genetic evolution and microenvironment interactions
FS Varn, KC Johnson, J Martinek, JT Huse, MLP Nasrallah, P Wesseling, ...Cell 185 (12), 2184-2199. e16, 2022202
87
2022
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma
S Wu, X Li, F Gao, JF De Groot, D Koul, WKA YungNeuro-oncology 23 (6), 920-931, 2021202
51
2021
Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation
N Noureen, S Wu, Y Lv, J Yang, WK Alfred Yung, J Gelfond, X Wang, ...Nature communications 12 (1), 139, 2021202
31
2021
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
M van den Bent, A Azaro, F De Vos, J Sepulveda, WKA Yung, PY Wen, ...Journal of neuro-oncology 146, 79-89, 2020202
27
2020
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
S Wu, F Gao, S Zheng, C Zhang, E Martinez-Ledesma, R Ezhilarasan, ...Clinical Cancer Research 26 (6), 1395-1407, 2020202
27
2020
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
VK Puduvalli, J Wu, Y Yuan, TS Armstrong, E Vera, J Wu, J Xu, P Giglio, ...Neuro-oncology 22 (10), 1505-1515, 2020202
23
2020
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
I Liu, L Jiang, ER Samuelsson, S Marco Salas, A Beck, OA Hack, D Jeong, ...Nature Genetics 54 (12), 1881-1894, 2022202
21
2022
TIE2–FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PlK1/CDK1 signaling in glioblastoma
X Li, E Martinez-Ledesma, C Zhang, F Gao, S Zheng, J Ding, S Wu, ...Cancer Research 79 (19), 5088-5101, 191
20
2019
Adenoviruses expressing heterologous tumor-associated antigens
J Fueyo-Margareto, C Gomez-Manzano, WKA Yung, V Krasnykh, H JiangUS Patent 11,155,599, 2021202
19
2021
The promise of DNA damage response inhibitors for the treatment of glioblastoma
NK Majd, TA Yap, D Koul, V Balasubramaniyan, X Li, S Khan, KS Gandy, ...Neuro-Oncology Advances 3 (1), vdab015, 2021202
18
2021
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center
RA Harrison, MD Anderson, D Cachia, C Kamiya-Matsuoka, ...European Journal of Cancer 112, 83-93, 2019201
17
2019
Prospective clinical sequencing of adult glioma
S Zheng, K Alfaro-Munoz, W Wei, X Wang, F Wang, AK Eterovic, ...Molecular cancer therapeutics 18 (5), 991-1000, 2019201
14
2019
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-1 experienceEQ Lee, W Selig, C Meehan, J Bacha, A Barone, E Bloomquist, ...Neuro-oncology 23 (8), 1252-1260, 2021202
9
2021
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials
BM Ellingson, MS Brown, JL Boxerman, ER Gerstner, TJ Kaufmann, ...Neuro-oncology 23 (2), 19-19, 2021202
8
2021
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
H Chen, J Kuhn, KR Lamborn, LE Abrey, LM DeAngelis, F Lieberman, ...Neuro-Oncology Advances 2 (1), vdaa124, 2020202
7
2020
GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
MB Buxton, BM Alexander, DA Berry, WK Cavenee, H Colman, ...Journal of Clinical Oncology 38 (15_suppl), TPS259-TPS259, 2020202
7
2020
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors
BM Ellingson, ER Gerstner, AB Lassman, C Chung, H Colman, PE Cole, ...Neuro-oncology 24 (8), 1219-1229, 2022202
7
2022

Referred From: https://scholar.google.com/citations?user=ykQG6qIAAAAJ&hl=en

Cited by
Citations 50844
h-index 103
i10-index 264
Recommended Journals
Open Access Journals